Histologic evidence of active liver injury in chronic hepatitis b patients with normal range or minimally elevated alanine aminotransferase levels

Journal of Clinical Gastroenterology

Volumn 44, Issue 7, 2010, Pages 510-516

  Hu, Ke Qin ^a   Schiff, Eugene R ^c   Kowdley, Kris V ^d   Min, Albert D ^e   Shiffman, Mitchell L ^f   Lee, William M ^g   Goodman, Zachary D ^h   Dau, Lauren O ^b   Peschell, Kenneth J ^b   Fagan, Elizabeth A ^b   Flaherty, John F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical Affairs   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e Veterans Administration   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

alanine aminotransferase; ALT; chronic hepatitis B

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; MALE; PRIORITY JOURNAL; BIOPSY; BLOOD; CLINICAL TRIAL (TOPIC); LIVER; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77955148095     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181d34c65     Document Type: Article

References (17)

1. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075.
2. Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760-767.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507-539.
4. Tsang PS, Trinh H, Garcia RT, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6:569-574.
5. Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341.
6. Green JL, Campagna E, Bogdan GM, et al. Effects of clinical laboratory choice on study outcome: an interlaboratory evaluation of aminotransferase levels. Pharmacotherapy. 2008;28: 453-457.
7. Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006;26: 445-450.
8. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983.
9. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610-1614.
10. Nguyen MH, Garcia RT, Trinh HN, et al. Histologic disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase level. Am J Gastroenterol. 2009;104:2206-2213.
11. Park J, Park Y, Kim D, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008;15:615-621.
12. Gui H, Xie Q, Wang H, et al. Predictors of Significant Histo- Logical Findings in Chronic Hepatitis B Patients with Persistently Normal ALT Levels (program no. 936). 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 2007. Abstract 936.
13. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
14. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816. (Pubitemid 36245757)
15. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
16. Fung J, Lai C, But D, et al. Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis b: Implications for Treatment and Management (program no. 922). 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 2007.
17. Wang CC, Lim LY, Deubner H, et al. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT (manuscript). J Clin Gastroenterol. 2008;42:820-826.